Mayo Clinic Study of Humanigen’s lenzilumab showed rapid recovery and discharged in severe and critical COVID-19 patients
On Jun. 15, 2020, Humanigen announced data on the first clinical use of lenzilumab in 12 COVID-19 patients. The manuscript, titled ﾑFirst Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia was published online at medRxiv.org.
Patients showed rapid clinical improvement with a median time to recovery of five days, median time to discharge of five days and 100% survival to the data cut-off date.
Tags:
Source: National Library of Medicine
Credit:
